Results 31 to 40 of about 4,744 (194)

Uncovering the roles of dihydropyrimidine dehydrogenase in fatty-acid induced steatosis using human cellular models

Scientific Reports, 2022
Pyrimidine catabolism is implicated in hepatic steatosis. Dihydropyrimidine dehydrogenase (DPYD) is an enzyme responsible for uracil and thymine catabolism, and DPYD human genetic variability affects clinically observed toxicity following 5-Fluorouracil ...
Kelly E. Sullivan, Sheetal Kumar, Xin Liu, Ye Zhang, Emily de Koning, Yanfei Li, Jing Yuan, Fan Fan   +7 more
doaj   +1 more source

Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia

Frontiers in Pharmacology, 2023
Background: Fluoropyrimidine toxicity is often due to variations in the gene (DPYD) encoding dihydropyrimidine dehydrogenase (DPD). DPYD genotyping can be used to adjust doses to reduce the likelihood of fluoropyrimidine toxicity while maintaining ...
Angela Wu, Angela Wu, Helen Anderson, Curtis Hughesman, Sean Young, Sean Young, Caroline Lohrisch, Colin J. D. Ross, Colin J. D. Ross, Bruce C. Carleton, Bruce C. Carleton, Bruce C. Carleton, Bruce C. Carleton   +12 more
doaj   +1 more source

DPYD Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation

Current Oncology, 2023
Fluoropyrimidine chemotherapy is associated with interpatient variability in toxicity. A major contributor to unpredictable and severe toxicity relates to single nucleotide variation (SNV) in dihydropyrimidine dehydrogenase (DPYD), the rate-limiting ...
Theodore J. Wigle, Samantha Medwid, Cameron Ross, Ute I. Schwarz, Richard B. Kim   +4 more
doaj   +1 more source

SNPs and Haplotypes in DPYD and Outcome of Capecitabine–Letter [PDF]

Clinical Cancer Research, 2011
In their recently published article in Clinical Cancer Research , Deenen and colleagues reported a number of single-nucleotide polymorphisms (SNP) and haplotypes in DPYD that were associated with toxicity of capecitabine ([1][1]).
van Kuilenburg André B P, Largiadèr Carlo R   +1 more
openaire   +6 more sources

Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis

BMC Cancer, 2017
Background To evaluate a new UGT1A and DPYD polymorphism panel to better predict irinotecan-induced toxicity and the clinical response in Chinese patients with metastatic colorectal cancer (mCRC).
Dan Liu, Jian Li, Jing Gao, Yanyan Li, Rui Yang, Lin Shen   +5 more
doaj   +1 more source

Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity [PDF]

, 2016
The objective of this study was to determine whether genotyping of MIR27A polymorphisms rs895819A>G and rs11671784C>T can be used to improve the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity
Meulendijks, Didier, Schellens, Jan H M, Beijnen, JH, Largiadèr, Carlo R, Henricks, LM, de Boer, Anthonius, Deenen, MJ, Meulendijks, D, de Boer, A, Henricks, Linda M, Cats, A, Schellens, JHM, Froehlich, Tanja K, Deenen, Maarten J, Sub Pharmacotherapy, Theoretical, Cats, Annemieke, Pharmacoepidemiology and Clinical Pharmacology, Fröhlich, Tanja, Sub Clinical Pharmacology, Amstutz, Ursula, Largiadèr, Carlo Rodolfo, Beijnen, Jos H   +21 more
core   +3 more sources

A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening [PDF]

Frontiers in Oncology, 2018
Background: The fluoropyrimidine anticancer drug, especially 5- fluorouracil (5-FU) and its prodrug capecitabine are still being the backbone of chemotherapeutic regimens for colorectal cancer. Dihydropyrimidine dehydrogenase (DPD) is the crucial enzyme in the catabolism of 5-FU.
Chi C. Tong, Ching W. Lam, Ka O. Lam, Victor H. F. Lee, Mai-Yee Luk   +4 more
openaire   +3 more sources

Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines

, 2015
Pre-therapeutic DPYD pharmacogenetic test to prevent fluoropyrimidines (FL)-related toxicities is not yet common practice in medical oncology. We aimed at investigating the clinical validity of DPYD genetic analysis in a large series of oncological ...
Lo Re, Giovanni, Scalone, Simona, Montico, Marcella, De Paoli, Antonino, GIODINI, LUCIANA, Toffoli, Giuseppe, Cecchin, Erika, GAGNO, SARA, Berretta, Massimiliano, Mini, Enrico, Buonadonna, Angela, RONCATO, ROSSANA, Lonardi, Sara, Miolo, Gianmaria, Pella, Nicoletta, Dreussi, Eva, Nobili, Stefania   +16 more
core   +2 more sources

Exploration and Validation of Pancreatic Cancer Hub Genes Based on Weighted Gene Co-Expression Network Analysis and Immune Infiltration Score Analysis

Pharmacogenomics and Personalized Medicine, 2023
Xiao-Xi Li,1,* Hong Li,2,* Li-Quan Jin,3 Yun-Bo Tan1,3 1Dali University of Clinical Medicine School, Dali, Yunnan, 671000, People’s Republic of China; 2Department of Radiology, Affiliated Renhe Hospital of China Three Gorges University, Hubei ...
Li XX, Li H, Jin LQ, Tan YB
doaj  

Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients

BMC Cancer, 2010
Background Severe toxicity to 5-fluorouracil (5-FU) based chemotherapy in gastrointestinal cancer has been associated with constitutional genetic alterations of the dihydropyrimidine dehydrogenase gene (DPYD).
Savva-Bordalo Joana, Ramalho-Carvalho João, Pinheiro Manuela, Costa Vera L, Rodrigues Ângelo, Dias Paula C, Veiga Isabel, Machado Manuela, Teixeira Manuel R, Henrique Rui, Jerónimo Carmen   +10 more
doaj   +1 more source